Tags

Type your tag names separated by a space and hit enter

Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
J Alzheimers Dis. 2014; 41(3):801-7.JA

Abstract

BACKGROUND

Two approaches are available for measuring Alzheimer's disease (AD) pathology in vivo. Biomarkers in cerebrospinal fluid (CSF) include amyloid-β1-42 (Aβ42) and tau. Furthermore, amyloid deposition can be visualized using positron emission tomography (PET) and [11C]Pittsburgh compound-B ([11C]PIB).

OBJECTIVE

We investigated concordance between CSF biomarkers and [11C]PIB PET as markers for AD pathology in a memory clinic cohort.

METHODS

We included 64 AD patients, 34 non-AD dementia patients, 22 patients with mild cognitive impairment (MCI), and 16 controls. [11C]PIB scans were visually rated as positive or negative. CSF biomarkers were considered abnormal based on Aβ42 alone (<550 ng/L), a more lenient Aβ42 cut-off (<640 ng/L) or a combination of both Aβ42 and tau ((373 + 0.82 tau)/Aβ42 > 1). Concordance between CSF biomarkers and [11C]PIB PET was determined.

RESULTS

Overall, concordance between [11C]PIB PET and CSF Aβ42 (<550 ng/L) was 84%. In discordant cases, [11C]PIB PET was more often AD-positive than Aβ42. When a more lenient Aβ42 cut-point (<640 ng/L) or a combination of Aβ42 and tau was used, concordance with [11C]PIB PET appeared to be even higher (90% and 89%). This difference is explained by a subgroup of mostly MCI and AD patients with Aβ42 levels just above cut-off. Now, in discordant cases, CSF was more often AD-positive than [11C]PIB PET.

CONCLUSION

Concordance between CSF Aβ42 and [11C]PIB PET was good in all diagnostic groups. Discordance was mostly seen in MCI and AD patients close to the cut-point. These results provide convergent validity for the use of both types of biomarkers as measures of AD pathology.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Zwan M
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands Department of Radiology & Nuclear Medicine, VU University Medical Center, MB Amsterdam, The Netherlands.
van Harten A
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands.
Ossenkoppele R
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands Department of Radiology & Nuclear Medicine, VU University Medical Center, MB Amsterdam, The Netherlands.
Bouwman F
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands.
Teunissen C
Department of Epidemiology and Biostatistics, VU University Medical Center, MB Amsterdam, The Netherlands.
Adriaanse S
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands Department of Radiology & Nuclear Medicine, VU University Medical Center, MB Amsterdam, The Netherlands.
Lammertsma A
Department of Radiology & Nuclear Medicine, VU University Medical Center, MB Amsterdam, The Netherlands.
Scheltens P
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands.
van Berckel B
Department of Radiology & Nuclear Medicine, VU University Medical Center, MB Amsterdam, The Netherlands.
van der Flier W
Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, The Netherlands Department of Epidemiology and Biostatistics, VU University Medical Center, MB Amsterdam, The Netherlands.

MeSH

AgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsBenzothiazolesCohort StudiesFemaleHumansMaleMemory DisordersMiddle AgedNeuropsychological TestsPeptide FragmentsPositron-Emission TomographyPsychiatric Status Rating ScalesThiazolestau Proteins

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24705549

Citation

Zwan, Marissa, et al. "Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort." Journal of Alzheimer's Disease : JAD, vol. 41, no. 3, 2014, pp. 801-7.
Zwan M, van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis. 2014;41(3):801-7.
Zwan, M., van Harten, A., Ossenkoppele, R., Bouwman, F., Teunissen, C., Adriaanse, S., Lammertsma, A., Scheltens, P., van Berckel, B., & van der Flier, W. (2014). Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. Journal of Alzheimer's Disease : JAD, 41(3), 801-7. https://doi.org/10.3233/JAD-132561
Zwan M, et al. Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. J Alzheimers Dis. 2014;41(3):801-7. PubMed PMID: 24705549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. AU - Zwan,Marissa, AU - van Harten,Argonde, AU - Ossenkoppele,Rik, AU - Bouwman,Femke, AU - Teunissen,Charlotte, AU - Adriaanse,Sofie, AU - Lammertsma,Adriaan, AU - Scheltens,Philip, AU - van Berckel,Bart, AU - van der Flier,Wiesje, PY - 2014/4/8/entrez PY - 2014/4/8/pubmed PY - 2015/9/19/medline KW - Alzheimer's disease KW - amyloid KW - cerebrospinal fluid KW - positron-emission tomography KW - tau SP - 801 EP - 7 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 41 IS - 3 N2 - BACKGROUND: Two approaches are available for measuring Alzheimer's disease (AD) pathology in vivo. Biomarkers in cerebrospinal fluid (CSF) include amyloid-β1-42 (Aβ42) and tau. Furthermore, amyloid deposition can be visualized using positron emission tomography (PET) and [11C]Pittsburgh compound-B ([11C]PIB). OBJECTIVE: We investigated concordance between CSF biomarkers and [11C]PIB PET as markers for AD pathology in a memory clinic cohort. METHODS: We included 64 AD patients, 34 non-AD dementia patients, 22 patients with mild cognitive impairment (MCI), and 16 controls. [11C]PIB scans were visually rated as positive or negative. CSF biomarkers were considered abnormal based on Aβ42 alone (<550 ng/L), a more lenient Aβ42 cut-off (<640 ng/L) or a combination of both Aβ42 and tau ((373 + 0.82 tau)/Aβ42 > 1). Concordance between CSF biomarkers and [11C]PIB PET was determined. RESULTS: Overall, concordance between [11C]PIB PET and CSF Aβ42 (<550 ng/L) was 84%. In discordant cases, [11C]PIB PET was more often AD-positive than Aβ42. When a more lenient Aβ42 cut-point (<640 ng/L) or a combination of Aβ42 and tau was used, concordance with [11C]PIB PET appeared to be even higher (90% and 89%). This difference is explained by a subgroup of mostly MCI and AD patients with Aβ42 levels just above cut-off. Now, in discordant cases, CSF was more often AD-positive than [11C]PIB PET. CONCLUSION: Concordance between CSF Aβ42 and [11C]PIB PET was good in all diagnostic groups. Discordance was mostly seen in MCI and AD patients close to the cut-point. These results provide convergent validity for the use of both types of biomarkers as measures of AD pathology. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/24705549/Concordance_between_cerebrospinal_fluid_biomarkers_and_[11C]PIB_PET_in_a_memory_clinic_cohort_ DB - PRIME DP - Unbound Medicine ER -